CAR-T cell therapy in nephrology.

Area of Science:

• Immunology
• Nephrology
• Cell Therapy

Background:

• Immune-mediated kidney diseases involve dysregulated B cell and plasma cell activity.
• These conditions often resist standard immunosuppressive therapies.
• Chimeric antigen receptor T-cell (CAR-T) therapy is an emerging immunotherapeutic strategy.

Purpose of the Study:

• To review the current landscape of CAR-based therapies in nephrology.
• To explore the immunopathological rationale for CAR-T in kidney diseases.
• To outline future directions for CAR-T integration into clinical practice.

Main Methods:

• Review of recent clinical data and studies on CAR-T therapies in autoimmune and kidney disease settings.
• Evaluation of novel CAR-T platforms like chimeric autoantibody receptor (CAAR)-T cells and bispecific T-cell engagers (BiTEs).
• Assessment of CAR-T applications in kidney transplantation.

Main Results:

• CAR-T therapies demonstrate potent and durable depletion of pathogenic lymphocytes.
• Clinical data suggest CAR-T can induce immunological remission, restore tolerance, and improve renal outcomes.
• Emerging evidence supports CAR-T use in kidney transplantation, including desensitization and post-transplant disorders.

Conclusions:

• CAR-T therapy presents a promising new avenue for treating refractory immune-mediated kidney diseases.
• Novel CAR-T platforms and applications in transplantation are expanding treatment possibilities.
• Challenges in toxicity, patient selection, cost, and long-term safety require further investigation.